A258540 Stock Overview

Engages in cell therapy and medical device businesses. More details

A258540 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Does not have a meaningful market cap (₩5B)

Has not reported any financial data

Highly volatile share price over the past 3 months compared to the KR market

My Notes

Capture your thoughts, links and company narrative

SL Therapeutics, Inc. Competitors

TechnologyLtd

KOSDAQ:A043090

₩20.9b

Celemics

KOSDAQ:A331920

₩26.9b

WOOJUNG BIO

KOSDAQ:A215380

₩27.3b

Green Lifescience

KOSDAQ:A114450

₩35.0b

Price History & Performance

Summary of share price highs, lows and changes for SL Therapeutics
Historical stock prices
Current Share Price	₩886.00
52 Week High	₩2,260.00
52 Week Low	₩503.00
Beta	0
1 Month Change	-6.44%
3 Month Change	-22.96%
1 Year Change	47.91%
3 Year Change	-82.28%
5 Year Change	-88.08%
Change since IPO	-80.74%

Recent updates

Shareholder Returns

	A258540	KR Life Sciences	KR Market
7D	-0.3%	-0.9%	-1.6%
1Y	47.9%	36.8%	-9.1%

Return vs Industry: A258540 exceeded the KR Life Sciences industry which returned 36.8% over the past year.

Return vs Market: A258540 exceeded the KR Market which returned -9.1% over the past year.

Price Volatility

Is A258540's price volatile compared to industry and market?
A258540 volatility
A258540 Average Weekly Movement	15.9%
Life Sciences Industry Average Movement	8.9%
Market Average Movement	6.6%
10% most volatile stocks in KR Market	12.6%
10% least volatile stocks in KR Market	3.3%

Stable Share Price: A258540's share price has been volatile over the past 3 months compared to the KR market.

Volatility Over Time: A258540's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of KR stocks.

About the Company

Founded	Employees	CEO	Website
2011	n/a	Jong Sung Choi	www.stemlab.co.kr

SL Therapeutics, Inc. engages in cell therapy and medical device businesses. The company develops cell therapeutic solutions based on its cell reprogramming technology to treat various diseases with a focus on spinal cord injury, and age and genetically related diseases; and hair follicle cells, skin cells, and cells of the central nervous system. It also manufactures automated magnetic resonance imaging systems; and Supra Elite and Dexino bone mineral density measurement devices.

SL Therapeutics, Inc. Fundamentals Summary

How do SL Therapeutics's earnings and revenue compare to its market cap?
A258540 fundamental statistics
Market cap	₩4.62b
Earnings (TTM)	₩0
Revenue (TTM)	n/a

n/a

P/E Ratio

n/a

P/S Ratio

Is A258540 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A258540 income statement (TTM)
Revenue	₩0
Cost of Revenue	₩0
Gross Profit	₩0
Other Expenses	₩0
Earnings	₩0

Last Reported Earnings

n/a

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did A258540 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/20 16:15
End of Day Share Price	2024/12/20 00:00
Earnings	N/A
Annual Earnings	N/A

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

SL Therapeutics, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution